The Boland lab aims to study the molecular mechanisms that underlie cell cycle regulation as well as signal transduction by membrane proteins in health and diseasework at the intersection of Structural Biology, Molecular & Cell Biology and Chemical Biology. Their research leverages the latest developments in cryogenic electron microscopy (cryoEM) and uses complementary biophysical techniques (proteomics, light-microscopy, microfluidics, etc.).
Angela Steinauer’s lab focuses on the engineering of non-viral, protein-based nanocarriers for targeted RNA delivery. Inspired by viral nucleic acid-protein assemblies, her group adopts a bottom-up approach and utilizes protein design, biomolecular engineering, and directed evolution to construct carriers with tailored functionalities.
The Schuhmacher Lab is interested in answering outstanding questions in membrane biology. Their chemical biology approach opens the door to investigate the so far mostly invisible and thus secret work of lipids. In particular, they would like to understand the biological role of lipid diversity and their impact on signaling processes.
Pablo Rivera-Fuentes lab, draws from the fields of organic synthesis, molecular biology, protein engineering, single-molecule imaging, and artificial intelligence to develop small-molecule and protein tools to study the subcellular compartementalization of biological processes. Current research lines in our lab include the characterization of the redox states of mammalian organelles, the creation of chemigenetic markers and sensors for in vivo imaging, and the development of single-molecule peptide and protein identification technologies.
Sascha Hoogendoorn lab aims to study and perturb cellular signalling, with a particular interest in the primary cilium and the Hedgehog signalling pathway. Her research combines organic chemistry with cell biology and CRISPR/Cas9-based gene editing to develop molecules that enable further dissection and manipulation of ciliary signalling.
The ultimate goal of Christian Heinis lab is the development of therapeutics by developing peptide macrocycles for potential therapeutic application using phase based strategy and biological and chemical tools. His lab currently develops potent antagonists to a range of disease targets, following medical indications in which bicyclic peptides promise advantages over small molecules and monoclonal antibodies.